Characterization of the in vivo immune network of IDO, tryptophan metabolism, PD-L1, and CTLA-4 in circulating immune cells in melanoma

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Oncoimmunology

• Publication date

  2015-03-04

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.4161/2162402X.2014.982382PMID 25949897PMCID PMC4404886
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Peritumoral indoleamine 2,3‐dioxygenase expression in melanoma: an early marker of resistance to immune control?

  2014cited by this paper
• Harnessing the immune system to provide long-term survival in patients with melanoma and other solid tumors

  2014cited by this paper
• Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab

  2014cited by this paper
• Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4

  2013cited by this paper
• Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells

  2013influential reference
• Myeloid‐derived suppressor cells in cancer: recent progress and prospects

  2013cited by this paper
• Metabolites of tryptophan catabolism are elevated in sera of patients with myelodysplastic syndromes and inhibit hematopoietic progenitor amplification.

  2013cited by this paper
• Myeloid-Derived Suppressor Cells Suppress Antitumor Immune Responses through IDO Expression and Correlate with Lymph Node Metastasis in Patients with Breast Cancer

  2013cited by this paper
• Host Indoleamine 2,3-Dioxygenase: Contribution to Systemic Acquired Tumor Tolerance

  2012cited by this paper
• An immune-active tumor microenvironment favors clinical response to ipilimumab

  2012cited by this paper
• Immune mediated mechanisms of melanocyte destruction

  2012cited by this paper
• The blockade of immune checkpoints in cancer immunotherapy

  2012influential reference
• Crosstalk between regulatory T cells (Tregs) and myeloid derived suppressor cells (MDSCs) during melanoma growth

  2012cited by this paper
• Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?

  2012cited by this paper
• Indoleamine 2,3-dioxygenase, a new prognostic marker in sentinel lymph nodes of melanoma patients.

  2012cited by this paper
• Myeloid-derived suppressor cell quantity prior to treatment with ipilimumab at 10mg/kg to predict for overall survival in patients with metastatic melanoma.

  2012cited by this paper
• A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma

  2011cited by this paper
• Identification of a Variable Number of Tandem Repeats Polymorphism and Characterization of LEF-1 Response Elements in the Promoter of the IDO1 Gene

  2011cited by this paper
• P032. Indoleamine 2,3 dioxygenase: a new prognostic marker in sentinel lymph nodes of melanoma patients

  2011cited by this paper
• Improved survival with ipilimumab in patients with metastatic melanoma.

  2010cited by this paper
• Increased indoleamine 2,3-dioxygenase (IDO) activity and elevated serum levels of tryptophan catabolites in patients with chronic kidney disease: a possible link between chronic inflammation and uraemic symptoms.

  2009cited by this paper
• Simultaneous measurement of tryptophan and related compounds by liquid chromatography/electrospray ionization tandem mass spectrometry.

  2008cited by this paper
• Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses.

  2007cited by this paper
• Decreased Serum Tryptophan Concentration Predicts Poor Prognosis in Malignant Melanoma Patients

  2006cited by this paper
• IDO expression on decidual and peripheral blood dendritic cells and monocytes/macrophages after treatment with CTLA-4 or interferon-gamma increase in normal pregnancy but decrease in spontaneous abortion.

  2005cited by this paper
• Association of Interferon‐gamma +874(T/A) Single Nucleotide Polymorphism with the Rate of Tryptophan Catabolism in Healthy Individuals

  2005cited by this paper
• Potential Regulatory Function of Human Dendritic Cells Expressing Indoleamine 2,3-Dioxygenase

  2002cited by this paper
• CTLA-4–Ig regulates tryptophan catabolism in vivo

  2002cited by this paper
• Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma.

  2001cited by this paper
• Relationship between interferon‐γ, indoleamine 2,3‐dioxygenase, and tryptophan catabolism

  1991cited by this paper

• Immunomodulatory mechanisms driving tumor escape in Glioblastoma: the central role of IDO and tryptophan metabolism in local and systemic immunotolerance.

  2025cites this paper
• Role of Tryptophan Metabolism in Cancer

  2025cites this paper
• Bifurcation and chaos in tumor-immune dynamics with IL-2: A comparative study of continuous and discrete-time models

  2025cites this paper
• Cellular Potency Optimization of Novel Heme-Binding Imidazo[5,1-b]thiazoles, Imidazo[1,5-a]pyridines and Pyrazines as Potent IDO1 Inhibitors Devoid of Cytochrome P450 Inhibition.

  2025cites this paper
• The paradoxical role of IFN-γ in cancer: Balancing immune activation and immune evasion.

  2025cites this paper
• Indoleamine 2,3-dioxygenase-1 expression in non-small-cell lung cancer: analyses of prevalence, clinical correlations and prognostic impact in 2 large patient cohorts

  2025cites this paper
• SynNotch CAR-T cell, when synthetic biology and immunology meet again

  2025cites this paper
• Immune Checkpoint Molecules: A Review on Pathways and Immunotherapy Implications

  2025cites this paper
• CD47 as a potent target in cancer immunotherapy: A review.

  2025cites this paper
• Innate immune cells in tumor microenvironment: A new frontier in cancer immunotherapy

  2024cites this paper
• A review of carbohydrate polymer-synthesized nanoparticles in cancer immunotherapy: Past, present and future perspectives.

  2024cites this paper
• Molecular mechanisms and therapeutic significance of Tryptophan Metabolism and signaling in cancer

  2024cites this paper
• Multi-functional nanomedicines for combinational cancer immunotherapy that transform cold tumors to hot tumors

  2024cites this paper
• Exploring the role of pyroptosis in shaping the tumor microenvironment of colorectal cancer by bulk and single-cell RNA sequencing

  2023cites this paper
• Applications of Innovation Technologies for Personalized Cancer Medicine: Stem Cells and Gene-Editing Tools.

  2023cites this paper
• Construction and application of microneedle-mediated photothermal therapy and immunotherapy combined anti-tumor drug delivery system

  2023cites this paper
• Targeting the tumor microenvironment by liposomal Epacadostat in combination with liposomal gp100 vaccine

  2023cites this paper
• “To be or not to Be”: Regulatory T cells in melanoma

  2023cites this paper
• Prospects and feasibility of synergistic therapy with radiotherapy, immunotherapy, and DNA methyltransferase inhibitors in non-small cell lung cancer

  2023cites this paper
• Natural Killer T and Natural Killer Cell-Based Immunotherapy Strategies Targeting Cancer

  2023cites this paper
• Partners in crime: The feedback loop between metabolic reprogramming and immune checkpoints in the tumor microenvironment

  2023cites this paper
• Recent Trends and Opportunities for the Targeted Immuno-Nanomaterials for Cancer Theranostics Applications

  2022cites this paper
• HSP90α induces immunosuppressive myeloid cells in melanoma via TLR4 signaling

  2022cites this paper
• Role of Immune Cells and Receptors in Cancer Treatment: An Immunotherapeutic Approach

  2022cites this paper
• Indoleamine 2,3‐dioxygenase gene expression and kynurenine to tryptophan ratio correlation with nasopharyngeal carcinoma progression and survival

  2022cites this paper
• IDO1 is highly expressed in macrophages of patients in advanced tumour stages of oral squamous cell carcinoma

  2022cites this paper
• Occurrence of hyperprogressive disease following administration of immune checkpoint inhibitors in lung squamous cell carcinoma: A case report

  2022cites this paper
• Metabolic rewiring directs melanoma immunology

  2022cites this paper
• T Lymphocyte Exhaustion During Human and Experimental Visceral Leishmaniasis

  2022cites this paper
• Immunotherapy resistance of lung cancer

  2022cites this paper
• Targeting Tryptophan Catabolism in Cancer Immunotherapy Era: Challenges and Perspectives

  2022cites this paper
• 肺癌免疫治疗耐药机制及应对策略

  2021cites this paper
• Targeting galectins in T cell-based immunotherapy within tumor microenvironment.

  2021cites this paper
• Immune Cell-Derived Extracellular Vesicles – New Strategies in Cancer Immunotherapy

  2021cites this paper
• Prognostic significance of CD204 and IDO1 expression in esophageal tumors

  2021cites this paper
• Immunobiology of Melanoma.

  2021cites this paper
• Targeting myeloid-derived suppressor cells for cancer therapy

  2021cites this paper
• Exploiting the CRISPR‐Cas9 gene‐editing system for human cancers and immunotherapy

  2021cites this paper
• Novel Combination Therapies for the Treatment of Bladder Cancer

  2021cites this paper
• Interferon-γ: teammate or opponent in the tumour microenvironment?

  2021cites this paper
• The Advance Cancer Immunotherapy Techniques and the Future Perspective of Modified T Cell Therapy

  2021influential citation
• Novel immune checkpoints beyond PD-1 in advanced melanoma

  2021cites this paper
• Metabolic Regulation of Myeloid-Derived Suppressor Cell Function in Cancer

  2020cites this paper
• Cancer immunotherapy: Pros, cons and beyond.

  2020cites this paper
• Plasmacytoid Dendritic Cells Protect Against Middle Cerebral Artery Occlusion Induced Brain Injury by Priming Regulatory T Cells

  2020cites this paper
• Innovative Precision Gene‐Editing Tools in Personalized Cancer Medicine

  2020cites this paper
• Functional Role of Dendritic Cell Subsets in Cancer Progression and Clinical Implications

  2020cites this paper
• Myeloid Cells as Clinical Biomarkers for Immune Checkpoint Blockade

  2020cites this paper
• Bispecific anti-PD-1/CTLA-4 antibody for advanced solid tumors.

  2020cites this paper
• IDO Expression in Cancer: Different Compartment, Different Functionality?

  2020influential citation
• FoxP3, CTLA-4, and IDO in Canine Melanocytic Tumors

  2020cites this paper
• Platelet Induced Functional Alteration of CD4+ and CD8+ T Cells in HNSCC

  2020cites this paper
• The Influence of Tumor Microenvironment on Immune Escape of Melanoma

  2020cites this paper
• Enhanced Anti-melanoma Efficacy of a Pim-3-Targeting Bifunctional Small Hairpin RNA via Single-Stranded RNA-Mediated Activation of Plasmacytoid Dendritic Cells

  2019cites this paper
• Emerging Immunotherapy Options for BCG-unresponsive Non-muscle-invasive Bladder Cancer.

  2019influential citation
• Novel Targets for the Treatment of Melanoma

  2019cites this paper
• Melanom

  2019cites this paper
• Unraveling the crosstalk between melanoma and immune cells in the tumor microenvironment.

  2019cites this paper
• Immunocyte Profiling Using Single-Cell Mass Cytometry Reveals EpCAM+ CD4+ T Cells Abnormal in Colon Cancer

  2019cites this paper
• Recent perspective on CAR and Fcγ-CR T cell immunotherapy for cancers: Preclinical evidence versus clinical outcomes.

  2019cites this paper
• Lymphopenia in Cancer Patients and its Effects on Response to Immunotherapy: an opportunity for combination with Cytokines?

  2019cites this paper
• Immune Markers in Non-Small Cell Lung Cancer: What Else Beyond Pd-L1 and Tumour Mutational Burden is there?

  2019cites this paper
• PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer

  2019cites this paper
• Differential Kinase Activation in Peripheral Blood Mononuclear Cells from Non-Small-Cell Lung Cancer Patients Treated with Nivolumab

  2019cites this paper
• Plasmacytoid pre-dendritic cells (pDC): from molecular pathways to function and disease association.

  2018cites this paper
• Chapter 6 Immunotherapy in Gynecologic Cancers

  2018cites this paper
• Title Early Immune Regulatory Changes in a Primary Controlled Human Plasmodium vivax Infection : CD 1 c + Myeloid Dendritic Cell Maturation Arrest , Induction of the Kynurenine Pathway , and Regulatory T Cell Activation

  2018cites this paper
• MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation

  2018cites this paper
• The Emerging Role of CD244 Signaling in Immune Cells of the Tumor Microenvironment

  2018cites this paper
• Defective levels of both circulating dendritic cells and T-regulatory cells correlate with risk of recurrence in cutaneous melanoma

  2018cites this paper
• New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1

  2018cites this paper
• Reply to ‘Challenging PD-L1 expressing cytotoxic T cells as a predictor for response to immunotherapy in melanoma’

  2018cites this paper
• Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward

  2018influential citation
• Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma.

  2017cites this paper
• Discovery of IDO1 Inhibitors: From Bench to Bedside.

  2017cites this paper
• Immune biomarkers for prognosis and prediction of responses to immune checkpoint blockade in cutaneous melanoma

  2017cites this paper
• A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic response

  2017cites this paper
• IDO and galectin-3 hamper the ex vivo generation of clinical grade tumor-specific T cells for adoptive cell therapy in metastatic melanoma

  2017cites this paper
• Immunomodulatory Monoclonal Antibodies in Combined Immunotherapy Trials for Cutaneous Melanoma

  2017cites this paper
• Immune Cell Metabolism in Tumor Microenvironment.

  2017cites this paper
• Programmed cell death-1 pathway inhibition in myeloid malignancies: implications for myeloproliferative neoplasms

  2017cites this paper
• The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy.

  2017cites this paper
• A flowcytometric analysis to efficiently quantify multiple innate immune cells and T Cell subsets in human blood

  2017cites this paper
• TRYPTOPHAN AND INDOLEAMINE-2,3-DIOXYGENASE (IDO) IN PATHOGENESIS OF IMMUNOSUPPRESSIVE CLINICAL CONDITIONS

  2017cites this paper
• Myeloid-Derived Suppressor Cells in Some Oncohematological Diseases

  2017cites this paper
• A versatile system for rapid multiplex genome-edited CAR T cell generation

  2017cites this paper
• A phase II trial of stereotactic body radiotherapy with concurrent anti-PD1 treatment in metastatic melanoma: evaluation of clinical and immunologic response

  2017cites this paper
• Immunotherapy in Gynecologic Cancers

  2017cites this paper
• Phase 1 Dose Escalation Trial of Ipilimumab and Stereotactic Body Radiation Therapy in Metastatic Melanoma.

  2017cites this paper
• Early Immune Regulatory Changes in a Primary Controlled Human Plasmodium vivax Infection: CD1c+ Myeloid Dendritic Cell Maturation Arrest, Induction of the Kynurenine Pathway, and Regulatory T Cell Activation

  2017cites this paper
• Comprehensive T‐cell immunophenotyping and next‐generation sequencing of human papillomavirus (HPV)‐positive and HPV‐negative head and neck squamous cell carcinomas

  2017influential citation
• Indoleamine 2,3 dioxygenase as a prognostic and follow‐up marker in melanoma. A comparative study with LDH and S100B

  2017cites this paper
• Disease-Associated Plasmacytoid Dendritic Cells

  2017cites this paper
• Oncolytic Vesicular Stomatitis Virus as a Viro-Immunotherapy: Defeating Cancer with a “Hammer” and “Anvil”

  2017cites this paper
• Indoleamine 2,3‐dioxygenase regulates T cell activity through Vav1/Rac pathway

  2017cites this paper
• Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix

  2016cites this paper
• Monitoring of the Immune Dysfunction in Cancer Patients

  2016cites this paper
• CTLA4 blockade reduces immature myeloid cells in head and neck squamous cell carcinoma

  2016cites this paper
• Immunophenotyping of Stage III Melanoma Reveals Parameters Associated with Patient Prognosis.

  2016cites this paper
• Potential biomarker for checkpoint blockade immunotherapy and treatment strategy

  2016cites this paper